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iATTLESCARRED
ubgroup or Selection Bias?
atriuretic peptide testing has achieved an important role in
ardiology and particularly in heart failure (HF) (1,2). After
iagnostic and prognostic benefits have been proven, clinicians
ave been intrigued with its potential for patient clinical
anagement (3).
After 10 years of research and the publication of several
andomized trials, including the BATTLESCARRED (NT-
ro-BNP-Assisted Treatment To LEssen Serial Cardiac Read-
issions and Death) trial (4), natriuretic peptides are still
aught in “no-man’s land.” Although some benefits were
vident, the applicability to clinical practice remains question-
ble. In the BATTLESCARRED trial, only 998 (28%) patients
f 3,576 screened met the inclusion criteria, and 364 patients, or
pproximately 10% of the initial cohort, were finally random-
zed. It is also important to note that mortality was lower than
xpected in a hospitalized HF cohort. Along with this, the
ong-term benefit was observed only for patients 75 years of age
r younger, which is roughly the median age in an average HF
opulation (5).
When scrutinizing the reported trials, some other reasons for
he results obtained herein may be relevant. Instead of fishing
or statistical significance in subgroup analysis, it may be more
elevant to switch gears and test natriuretic peptides in settings
here most patients are managed and good clinical practice
annot be implemented as appropriate for various clinical and
ogistical reasons. The BATTLESCARRED trial, as well as
any other trials, already demonstrated that there is an impor-
ant gap between specialized HF settings and usual care
ettings. It has also been shown that natriuretic peptides may
revent unnecessary referrals from primary care (6). Along with
rimary care settings, patients with HF and preserved left
entricular ejection fraction may be 2 major fields of interest.
ext to that, natriuretic peptide-guided discharge and the
ddition of natriuretic peptide testing in patients with only
orderline indications for mechanical devices may prevent
ospitalizations. However, as clinicians, we always have to keep
n mind that we are managing patients and not laboratory
ndings (7), and no biomarker will ever replace experienced
linical judgment. Although the BATTLESCARRED trial did
ot make the final step on its mission, we firmly believe other
ridges with public health implications can be crossed. Whether
e are on point or whether we also failed will be judged in
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Question of Central Importance
omaschitz et al. (1) reported associations between plasma
ldosterone/renin ratio (ARR) and blood pressure (BP) in a
ohort of patients undergoing coronary artery angiography. A
ovel aspect of this study was assessment of both brachial and
ortic (central) BP. The focus on the risk related to BP remains
n conventional brachial cuff BP values. However, large differ-
nces (e.g., 30 mm Hg) in central systolic blood pressure
SBP) may occur between individuals with similar brachial SBP
2,3). The clinical implications of this central-to-peripheral BP
ifference was highlighted in a recent meta-analysis in which
entral BP indexes predicted cardiovascular events and mortal-
ty independent of brachial BP (4). Given that homeostatic
ontrol of blood volume and BP are dependent on central
